Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules

A. Fraternale, M. F. Paoletti, A. Casabianca, J. Oiry, P. Clayette, J. U. Vogel, Jr Cinatl, A. T. Palamara, R. Sgarbanti, E. Garaci, E. Millo, U. Benatti, M. Magnani

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Reduced glutathione (GSH) is present in millimolar concentrations in mammalian cells. It is involved in many cellular functions such as detoxification, amino acid transport, production of coenzymes, and the recycling of vitamins E and C. GSH acts as a redox buffer to preserve the reduced intracellular environment. Decreased glutathione levels have been found in numerous diseases such as cancer, viral infections, and immune dysfunctions. Many antioxidant molecules, such as GSH and N-acetylcysteine (NAC), have been demonstrated to inhibit in vitro and in vivo viral replication through different mechanisms of action. Accumulating evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the Th1/Th2 cytokine response pattern, and more precisely, GSH depletion inhibits Th1-associated cytokine production and/or favours Th2 associated responses. It is known that GSH is not transported to most cells and tissues in a free form. Therefore, a number of different approaches have been developed in the last years to circumvent this problem. This review discusses the capacity of some new molecules with potent pro-GSH effects either to exert significant antiviral activity or to augment GSH intracellular content in macrophages to generate and maintain the appropriate Th1/Th2 balance. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to treat antiviral infections and Th2-mediated diseases such as allergic disorders and AIDS.

Original languageEnglish
Pages (from-to)1749-1755
Number of pages7
JournalCurrent Medicinal Chemistry
Volume13
Issue number15
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Antiviral Agents
Glutathione
Macrophages
Th1-Th2 Balance
Cytokines
Molecules
Coenzymes
Acetylcysteine
Recycling
Antigen-Presenting Cells
Virus Diseases
Vitamin E
Ascorbic Acid
Oxidation-Reduction
Detoxification
Buffers
Acquired Immunodeficiency Syndrome
Antioxidants
Amino Acids
Infection

Keywords

  • Antigen presenting cells (APC)
  • GSH derivatives
  • Pro-GSH molecules
  • Reduced glutathione (GSH)
  • Th1/Th2 responses
  • Viral infection

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Fraternale, A., Paoletti, M. F., Casabianca, A., Oiry, J., Clayette, P., Vogel, J. U., ... Magnani, M. (2006). Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Current Medicinal Chemistry, 13(15), 1749-1755. https://doi.org/10.2174/092986706777452542

Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. / Fraternale, A.; Paoletti, M. F.; Casabianca, A.; Oiry, J.; Clayette, P.; Vogel, J. U.; Cinatl, Jr; Palamara, A. T.; Sgarbanti, R.; Garaci, E.; Millo, E.; Benatti, U.; Magnani, M.

In: Current Medicinal Chemistry, Vol. 13, No. 15, 06.2006, p. 1749-1755.

Research output: Contribution to journalArticle

Fraternale, A, Paoletti, MF, Casabianca, A, Oiry, J, Clayette, P, Vogel, JU, Cinatl, J, Palamara, AT, Sgarbanti, R, Garaci, E, Millo, E, Benatti, U & Magnani, M 2006, 'Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules', Current Medicinal Chemistry, vol. 13, no. 15, pp. 1749-1755. https://doi.org/10.2174/092986706777452542
Fraternale A, Paoletti MF, Casabianca A, Oiry J, Clayette P, Vogel JU et al. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Current Medicinal Chemistry. 2006 Jun;13(15):1749-1755. https://doi.org/10.2174/092986706777452542
Fraternale, A. ; Paoletti, M. F. ; Casabianca, A. ; Oiry, J. ; Clayette, P. ; Vogel, J. U. ; Cinatl, Jr ; Palamara, A. T. ; Sgarbanti, R. ; Garaci, E. ; Millo, E. ; Benatti, U. ; Magnani, M. / Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. In: Current Medicinal Chemistry. 2006 ; Vol. 13, No. 15. pp. 1749-1755.
@article{f599e5814c6448a4be6f5dee3ec08c53,
title = "Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules",
abstract = "Reduced glutathione (GSH) is present in millimolar concentrations in mammalian cells. It is involved in many cellular functions such as detoxification, amino acid transport, production of coenzymes, and the recycling of vitamins E and C. GSH acts as a redox buffer to preserve the reduced intracellular environment. Decreased glutathione levels have been found in numerous diseases such as cancer, viral infections, and immune dysfunctions. Many antioxidant molecules, such as GSH and N-acetylcysteine (NAC), have been demonstrated to inhibit in vitro and in vivo viral replication through different mechanisms of action. Accumulating evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the Th1/Th2 cytokine response pattern, and more precisely, GSH depletion inhibits Th1-associated cytokine production and/or favours Th2 associated responses. It is known that GSH is not transported to most cells and tissues in a free form. Therefore, a number of different approaches have been developed in the last years to circumvent this problem. This review discusses the capacity of some new molecules with potent pro-GSH effects either to exert significant antiviral activity or to augment GSH intracellular content in macrophages to generate and maintain the appropriate Th1/Th2 balance. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to treat antiviral infections and Th2-mediated diseases such as allergic disorders and AIDS.",
keywords = "Antigen presenting cells (APC), GSH derivatives, Pro-GSH molecules, Reduced glutathione (GSH), Th1/Th2 responses, Viral infection",
author = "A. Fraternale and Paoletti, {M. F.} and A. Casabianca and J. Oiry and P. Clayette and Vogel, {J. U.} and Jr Cinatl and Palamara, {A. T.} and R. Sgarbanti and E. Garaci and E. Millo and U. Benatti and M. Magnani",
year = "2006",
month = "6",
doi = "10.2174/092986706777452542",
language = "English",
volume = "13",
pages = "1749--1755",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules

AU - Fraternale, A.

AU - Paoletti, M. F.

AU - Casabianca, A.

AU - Oiry, J.

AU - Clayette, P.

AU - Vogel, J. U.

AU - Cinatl, Jr

AU - Palamara, A. T.

AU - Sgarbanti, R.

AU - Garaci, E.

AU - Millo, E.

AU - Benatti, U.

AU - Magnani, M.

PY - 2006/6

Y1 - 2006/6

N2 - Reduced glutathione (GSH) is present in millimolar concentrations in mammalian cells. It is involved in many cellular functions such as detoxification, amino acid transport, production of coenzymes, and the recycling of vitamins E and C. GSH acts as a redox buffer to preserve the reduced intracellular environment. Decreased glutathione levels have been found in numerous diseases such as cancer, viral infections, and immune dysfunctions. Many antioxidant molecules, such as GSH and N-acetylcysteine (NAC), have been demonstrated to inhibit in vitro and in vivo viral replication through different mechanisms of action. Accumulating evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the Th1/Th2 cytokine response pattern, and more precisely, GSH depletion inhibits Th1-associated cytokine production and/or favours Th2 associated responses. It is known that GSH is not transported to most cells and tissues in a free form. Therefore, a number of different approaches have been developed in the last years to circumvent this problem. This review discusses the capacity of some new molecules with potent pro-GSH effects either to exert significant antiviral activity or to augment GSH intracellular content in macrophages to generate and maintain the appropriate Th1/Th2 balance. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to treat antiviral infections and Th2-mediated diseases such as allergic disorders and AIDS.

AB - Reduced glutathione (GSH) is present in millimolar concentrations in mammalian cells. It is involved in many cellular functions such as detoxification, amino acid transport, production of coenzymes, and the recycling of vitamins E and C. GSH acts as a redox buffer to preserve the reduced intracellular environment. Decreased glutathione levels have been found in numerous diseases such as cancer, viral infections, and immune dysfunctions. Many antioxidant molecules, such as GSH and N-acetylcysteine (NAC), have been demonstrated to inhibit in vitro and in vivo viral replication through different mechanisms of action. Accumulating evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the Th1/Th2 cytokine response pattern, and more precisely, GSH depletion inhibits Th1-associated cytokine production and/or favours Th2 associated responses. It is known that GSH is not transported to most cells and tissues in a free form. Therefore, a number of different approaches have been developed in the last years to circumvent this problem. This review discusses the capacity of some new molecules with potent pro-GSH effects either to exert significant antiviral activity or to augment GSH intracellular content in macrophages to generate and maintain the appropriate Th1/Th2 balance. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to treat antiviral infections and Th2-mediated diseases such as allergic disorders and AIDS.

KW - Antigen presenting cells (APC)

KW - GSH derivatives

KW - Pro-GSH molecules

KW - Reduced glutathione (GSH)

KW - Th1/Th2 responses

KW - Viral infection

UR - http://www.scopus.com/inward/record.url?scp=33745035190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745035190&partnerID=8YFLogxK

U2 - 10.2174/092986706777452542

DO - 10.2174/092986706777452542

M3 - Article

VL - 13

SP - 1749

EP - 1755

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -